Apabetalone

Drug Profile

Apabetalone

Alternative Names: RVX-000222; RVX-208

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Resverlogix Corporation
  • Class Anti-inflammatories; Cardiovascular therapies; Quinazolines; Small molecules
  • Mechanism of Action Apolipoprotein A I stimulants; Bromodomain and extraterminal domain protein inhibitors; Chemokine CCL2 modulators; Interleukin 6 inhibitors; Monocyte inhibitors; Vascular cell adhesion molecule modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute coronary syndromes; Atherosclerosis; Low HDL cholesterol
  • Phase II Prediabetic-state
  • Phase I Alzheimer's disease
  • Preclinical Renal failure

Most Recent Events

  • 15 Mar 2017 Reseverlogix receives notice of allowance from USPTO for patent claims covering apabetalone in combination with rosuvastatin in the US
  • 27 Feb 2017 Resverlogix intends to files an IND application with the FDA in USA for Renal failure
  • 23 Feb 2017 Resverlogix plans a phase II trial for Renal failure in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top